New-Onset Atrial Fibrillation After Aortic Valve Replacement Comparison of Transfemoral, Transapical, Transaortic, and Surgical Approaches

ObjectivesThis study sought to determine the incidence of new-onset atrial fibrillation (AF) associated with different methods of isolated aortic valve replacement (AVR)—transfemoral (TF), transapical (TA), and transaortic (TAo) catheter-based valve replacement and conventional surgical approaches.BackgroundThe relative incidences of AF associated with the various access routes for AVR have not been well characterized.MethodsIn this single-center, retrospective cohort study, we evaluated a total of 231 consecutive patients who underwent AVR for degenerative aortic stenosis (AS) between March 2010 and September 2012. Patients with a history of paroxysmal, persistent, or chronic AF, with bicuspid aortic valves, and patients who died within 48 h after AVR were excluded. A total of 123 patients (53% of total group) qualified for inclusion. Data on documented episodes of new-onset AF, along with all clinical, echocardiographic, procedural, and 30-day follow-up data, were collated.ResultsAF occurred in 52 patients (42.3%). AF incidence varied according to the procedural method. AF occurred in 60% of patients who underwent surgical AVR (SAVR), in 53% after TA-TAVR, in 33% after TAo-TAVR cases, and 14% after TF-TAVR. The episodes occurred at a median time interval of 53 (25th to 75th percentile, 41 to 87) h after completion of the procedure. Procedures without pericardiotomy had an 82% risk reduction of AF compared with those with pericardiotomy (adjusted odds ratio: 0.18; 95% confidence interval: 0.05 to 0.59).ConclusionsAF was a common complication of AVR with a cumulative incidence of >40% in elderly patients with degenerative AS who underwent either SAVR or TAVR. AF was most common with SAVR and least common with TF-TAVR. Procedures without pericardiotomy were associated with a lower incidence of AF

Persistent Native Aortic Valve Function after Transcatheter Aortic Valve Replacement

WEBSITE FEATUR

Multimodality image guidance with Dyna-CT for transcatheter treatment of paravalvular leak of a stentless valve

The transcatheter treatment of paravalvular leaks (PVL) are technically challenging procedures; they pose increasing difficulty in cases where there is a stentless valve, without the usual fluoroscopic landmarks. Hence, there is limited experience in treating this defect percutaneously. We present a case of a patient with an aortic PVL of a stentless valve and how the integrated use of multi-imaging modalities (transesophageal echocardiography, computed tomography and rotational angiography) allowed the demarcation of landmarks onto live fluoroscopy and guided the transcatheter occlusion of the PVL

Transfemoral Aortic Valve Replacement in Failing Aortic Root Homografts

Transcatheter aortic valve implantation (TAVI) for failing aortic root and valve homografts has been described primarily via a transapical approach. We report the successful treatment of two patients with failing homografts by transfemoral (TF) TAVI. In both cases, TF TAVI was accomplished without technical difficulty and with good clinical outcomes. doi: 10.1111/jocs.12277 (J Card Surg 2014;29:333–336

Actin Regulation and Surface Catalysis

The motile behavior of non-muscle cells often differs between healthy and pathological conditions. Two disease processes, cancer and atherosclerosis, are associated with high morbidity and mortality in our society. The cells involved in both the pathogenesis of and me defense against these diseases undergo marked changes in the organization of their actin cytoskeletonl1,2. In response to a signal originating from the extracellular space, from surrounding cells, or as the result of a mutation, diseased cells initiate a process of motion away from their normal location. Local growth inhibitors are lost, and displaced cells undergo unchecked proliferation1. One example of such a phenomenon is the migration of fibroblasts and smooth muscle cells into the vascular intima and their proliferation in patients with atherosclerotic coronary artery disease2. Another example is the proliferation of metastatic cells distant from the site of primary tumor1